edicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (A61K47)

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex

Production and application of bacterial histamine // 2628536
FIELD: medicine.SUBSTANCE: method for selecting a probiotic lactic bacterial strain for use in the local production of histamine in a mammal is provided. A product and composition for the local production of histamine in a mammal containing a lactic acid bacterial strain having an active histidine operon and capable of producing histamine is proposed for use in the treatment and/or prevention of inflammatory conditions.EFFECT: local production of histamine in a mammal by selecting certain strains of lactic acid bacteria.13 cl, 9 dwg, 2 tbl, 5 ex

Immunocytocins combined therapy // 2628089
FIELD: pharmacology.SUBSTANCE: method for skin tumor treatment by TNF immunoconjugate single dose injectionα and IL-2 immunoconjugate single dose to tumor localization site, at that, injectable administration of TNF immunoconjugateα and IL-2 immunoconjugate is carried out simultaneously. TNF immunoconjugateα contains TNFα, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The IL-2 immunoconjugate comprises IL-2, bound to an antibody molecule that binds to the additional ED-B domain of the B-FN fibronectin splice isoform. The invention also relates to compositions for skin tumor treatment comprising the said TNF immunoconjugateα and/or the said IL-2 immunoconjugate.EFFECT: invention provides for stimulation of complete destruction of large subcutaneous tumors with a single local administration of a combination of TNF immunoconjugateα and IL-2 immunoconjugate.42 cl, 4 dwg

ethod of production of a combined antihelmint tablet with a symbiotic treatment for treatment of a small cattle // 2627893
FIELD: veterinary medicine.SUBSTANCE: invention is a method for producing a combined anthelmintic tablet with a symbiotic for treating small cattle containing a first and second layer comprising the steps of: adding a first powder mixture to a mould plate. Mentioned first powder mixture contains a pharmaceutically active substance and a binder, a second powder mixture is added to said mould plate. Mentioned second powder blend comprises a binder and the composition of mentioned second powder blend is different from the composition of mentioned first powder mixture, the first powder mixture and the second powder blend are pressed on said plate of the mould to form a tablet form and subjected to said tableted form with radio frequency emission for a period of Time sufficient to activate said binder within said tablet mould to fuse mentioned tableted Th form into said tablet, such that the density of mentioned tablet is less than about 0.8 g/cm3, characterized in that a bacterial concentrate is prepared for the preparation of the first powder mixture comprising a bifidobacterium adolescentis B-1 and Lactobacillus acidophilus LH-1 consortium with a titre of 108-1010 CFU/g sorbed on a carrier in a ratio of 1:1:12, which Is concentrated by filtration or centrifugation to a suspension containing 5 billion bacteria per ml, followed by mixing them in equal volumes. As the carrier, flour or bran is used at the rate of 12 parts of the support per part of a mixture of concentrated cultures, and then the obtained dry powder mass is mixed with lactulose, and to obtain the second powder mixture, ivermectin, praziquantel and at least one pharmaceutically acceptable excipient microcrystalline cellulose MCC is used, then the substances ivermectin, praziquantel and excipient are mixed in dry kind. The components in the tablet are in a certain ratio in wt %.EFFECT: invention provides high anthelmintic activity, intensification of treatment and prevention of a number of helminthic invasions, nonspecific correction of the immune response of the animal organism, normalization of hepatoprotective and reparative liver functions.6 ex, 1 tbl, 1 dwg

eans for left ventricle diastolic function improvement // 2627842
FIELD: pharmacology.SUBSTANCE: application of 4-[(2-{(2R)-2-((1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid, or a salt thereof, of its clathrate complex with cyclodextrin for preparation of means 1) for treatment of diastolic heart failure and/or symptom alleviation; 2) for heart failure treatment, at which the diastolic function is weakened; 3) for left ventricle diastolic function improvement; 4) for left ventricle expansion improvement; 5) for left ventricle selective diastolic function improvement; 6) for diastolic functional insufficiency treatment or improvement; 7) for diastolic dysfunction treatment or improvement.EFFECT: agent improves diastolic function of the left ventricle itself, without dependence on diuretic influence or vasodilator effect, controls the pathological state of diastolic functional insufficiency and prevents relapse, can prevent dyspnea and death caused by a pathological condition, the agent can alleviate diastolic functional failure for which an effective therapeutic method has not been established.10 cl, 3 dwg, 5 tbl, 2 ex
ethod of producing nanocapules of l-arginine // 2627819
FIELD: nanotechnology.SUBSTANCE: method is characterized in that L-arginine is slowly added to a suspension of carrageenan in butyl alcohol in the presence of 0.01 E472c preparation as a surfactant with stirring at 1300 rpm. Then 5 ml of hexane are poured, the resulting suspension of the nanocapsules is filtered off and dried at room temperature. The mass ratio core: the shell is 1:3 or 1:1.EFFECT: simplification and acceleration of the process of obtaining nanocapsules.3 ex

Crystalline forms of 1-(3-tret-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyetil)-1h-indasol-5-yloxy)benzyl) hydrochloride urea // 2627702
FIELD: pharmacology.SUBSTANCE: invention relates to a crystalline polymorphic Form B of the hydrochloride salt of 1-(3-t-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl) urea, which is characterized by the presence of peaked diffraction peaks (degrees 2θ at ± 0.3) at about 12.3, 13.0, 15.9, 16.9 and 17.6 and to a pharmaceutical composition for proliferative disorders treatment comprising the said polymorphic Form B. The invention also relates to a method for proliferative diseases treatment with the claimed pharmaceutical composition, pharmaceutical composition and method application for preparation of the said polymorphic Form B.EFFECT: increased efficiency of treatment.89 cl, 7 dwg, 23 tbl, 10 ex
eans for teeth hard tissue remineralization // 2627624
FIELD: medicine.SUBSTANCE: proposed means for teeth hard tissues remineralization contains a component of the intended use - hydroxyapatite with high degree of purification, particle size of 20×150 nm, and a basis of 1500 and 400 polyethylene oxides in the following ratio, wt %: hydroxyapatite - 7, PEO 1500 - 74.4, PEO 400 - 18.6.EFFECT: increased resistance, acid resistance of teeth hard tissues, decreased enamel solubility, activation of the remineralization process, reduction of hyperesthesia, prevention of caries development, prevention of caries progression, prolongation of the remineralization effect due to a prolonged contact of the remineralizing gel with the surface of teeth hard tissues.1 tbl, 2 ex, 8 dwg
Antituberculosis pharmaceutical composition containing thioacetazone // 2627611
FIELD: pharmacology.SUBSTANCE: compositions for tuberculosis treatment include thioacetazone s active ingredient, as well as lactose, starch, talc and stearic acid and/or a salt thereof, at a certain quantitative ratio.EFFECT: invention allows to obtain a composition characterized by high solubility, bioavailability and efficacy.8 tbl, 6 ex

ethod of producing nanocapule of dry extract of briar in agar-agar // 2627585
FIELD: nanotechnology.SUBSTANCE: dry briar extract is slowly added to the agar-agar suspension in butanol in the presence of E472c as a surfactant with stirring at 1000 rpm. Then hexane is poured. After that, the precipitate is filtered off and dried at room temperature, the ratio of dry extract of briar to agar-agar is 1:1, 1:3 or 5:1.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.3 dwg, 4 ex

ethod of producing nanocapules of cyclophosphamide-lens // 2627584
FIELD: nanotechnology.SUBSTANCE: method of obtaining cyclophosphamide-LENS nanocapsules is characterized in that 0.5 g cyclophosphamide-LENS is slowly added to the suspension 0.1 g sodium alginate in butanol in the presence of 50 mg of E472c preparation as a surfactant with stirring at 1000 rpm, then 5 ml of diethyl ether are poured, the precipitate is filtered off and dried at room temperature.EFFECT: simplification and acceleration of nanocapsule production of cyclophosphamide-LENS, weight yield increase.1 dwg, 3 ex

ethod of obtaining nanocapsules of vera-ifosphamide in sodium alginate // 2627583
FIELD: nanotechnology.SUBSTANCE: vera-ifosphamide is slowly added to a suspension of sodium alginate in petroleum ether in the presence of E472c preparation as a surfactant with stirring at 1000 rpm, then methylene chloride is poured, the precipitate is filtered off and dried at room temperature. The mass ratio core: the envelope in nanocapsules is 5:1 or 1:1.EFFECT: acceleration and simplification of the process of obtaining the vera-ifosphamide nanocapsules, increasing their yield by mass.1 dwg, 3 ex

ethod of producing nanocapules of chloralhydrate in kappa-carraginane // 2627581
FIELD: nanotechnology.SUBSTANCE: chloral hydrate powder is added to a suspension of kappa-carrageenan in butanol and 0.01 g preparation E472c, used as a surfactant. Then 10 ml of methylene chloride is added, the resulting nanocapsule suspension is filtered off and dried. The mass ratio core: the shell in nanocapsules is 1:3 or 1:1.EFFECT: acceleration and simplification of the process of obtaining nanocapsules of chloralhydrate, and also increasing their yield by mass.1 dwg, 3 ex
ethod of obtaining nanocapules of antibiotics of tetracyclin row in konjac gum // 2627580
FIELD: nanotechnology.SUBSTANCE: antibiotics are selected from tetracycline, dioxycycline, minocycline, when the method is applied to a suspension of konjac gum in butanol and 0.01 g of E472c preparation as a surfactant, an antibiotic powder is added, then petroleum ether is added dropwise, which is used as a precipitant. The ratio of the amounts of antibiotic to the amount of konjac gum is 1:1, 1:3, 1:5 or 5:1, the resulting suspension of nanocapsules is filtered off and dried.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.4 dwg, 11 ex
ethod of obtaining nanocapules of metal salts in carraginan // 2627578
FIELD: nanotechnology.SUBSTANCE: carraginan is used as the nanocapsule shell, and the metal salt is used as the core for the mass ratio of the core: shell 1:3. The metal salt is added to a suspension of carraginan in ethanol containing the E472c preparation as a surfactant, with stirring at 1200 rpm, then methylene chloride is poured, the resulting suspension is filtered off and dried at room temperature.EFFECT: simplification and acceleration of the process of obtaining nanocapsules.11 ex
ethod of producing nanocapules of metal salts in sodium alginate // 2627577
FIELD: nanotechnology.SUBSTANCE: sodium alginate is used as the nanocapsule coating, and the metal salt is used as the core for the core to shell: 1:3 shell weight ratio, while the metal salt is added to a suspension of sodium alginate in butanol containing the E472c preparation as a surfactant with stirring 1200 rpm, then petroleum ether is poured, the resulting suspension is filtered off and dried at room temperature.EFFECT: simplification and acceleration of the process of obtaining nanocapsules.11 ex

Pharmaceutical compositions comprising oligomeric lactic acid // 2627470
FIELD: pharmacology.SUBSTANCE: invention provides a composition comprising i) an oligomeric lactic acid of formula (I) wherein n is an integer from 2 to 20, 2 to 19, or 2 to 18, and wherein the content of the oligomeric lactic acid which is a trimer, i.e, HL3, which coefficient n is 2, is approx. 10 to approx. 20 wt % of the oligomeric lactic acid total weight. The average molecular weight Mn of the oligomeric lactic acid is approx. 200 to approx. 500, and ii) a mucoadhesive agent. The oligomeric lactic acid content is 20 to 80 wt % and mucoadhesive agent content is from 10 to 65 wt %.EFFECT: improved properties.17 cl, 11 ex, 25 tbl, 9 dwg

Pharmaceutical compositions comprising water-insoluble antipsychotic agent and sorbitan esters // 2627469
FIELD: pharmacology.SUBSTANCE: invention relates to an injectable pharmaceutical composition for treatment of central nervous system disorders, comprising: (a) compound A-7: ,wherein component (a) is present in an amount of 15-35 wt %; (b) sorbitan laurate in an amount of 0.2-1 wt %; (c) polysorbate 20 in an amount of 0.05-0.8 wt %, and (d) an aqueous carrier. The invention also relates to a method for central nervous system disorders treatment, comprising administration of an effective amount of the said composition to a subject in need of such treatment.EFFECT: invention provides a composition which can be easily re-suspended, reduces local tissue response to antipsychotic means in sustained release formulations, and improves drugs compliance.11 cl, 4 tbl, 5 ex, 10 dwg

Formulations of 2-iminobiotine and use thereof // 2627460
FIELD: pharmaceutics.SUBSTANCE: present invention relates to 2-iminobiotine pharmaceutical aqueous composition, having pH from 3 to 7 and containing 1 mg/ml or more of 2-iminobiotine and from 2.5 to 40 % of substituted beta-cyclodextrin, wherein said substituted beta-cyclodextrin is selected from sulfobutylether-beta-cyclodextrin (SBE-CD) and hydroxypropyl-beta-cyclodextrin.EFFECT: invention provides creation of aqueous solution of 2-iminobiotine with high content of 2-iminobiotine (higher solubility of 2-iminobiotine), which is ensured by introduction of substituted beta-cyclodextrin into disclosed composition or citric acid/citrate buffer to ensure solution pH from 3 to 7.19 cl, 14 ex, 27 tbl, 1 dwg

Pharmaceutical niosomal gel based on n-hydroxy-2-(2-(naphtalene-2-yl)-1h-indole-3-yl)-2-phenylacetamide with anti-tumour activity to glioblastoma // 2627449
FIELD: pharmacology.SUBSTANCE: composition is a niosomal gel containing the niosome-encapsulated synthesized N-hydroxy-2-(2-(naphthalene-2-yl)-1H-indole-3-yl)-2-phenylacetamide.EFFECT: implementation of the invention allows to increase the efficiency of antitumor substance transport into the target cells, thereby increasing the therapeutic effect of the niosomal gel for the treatment of glioblastoma.1 tbl, 2 dwg

Compositions with controlled release and methods of their use // 2627429
FIELD: veterinary medicine.SUBSTANCE: composition contains the therapeutically effective amount of at least one active substance and the base, containing colloidal silicon dioxide in the concentration from 0.1 upto 5% by weight, at least one oil and at least one surface active agent in the concentration from 0.01 upto 10% by weight. The active agent is chosen from the group of antibiotics, containing betalactams, penicillins, cephalosporins, aminoglycosides, quinolones, sulfonamides, tetracyclines, macrolides and combinations thereof. The oil is selected from the group, consisting of triglycerides, light vaseline oil, ethyl oleate, sesame oil and peanut oil. The colloidal silicon dioxide is dispersed in the oil in the composition according to the invention. The viscosity of the composition is less than 1000 mPas at the shear rate of 100 1/s and at the temperature of 20°C. Also described the composition manufacturing method and application for treating or preventing measures of mastitis at the animal which need it.EFFECT: according to the invention the composition provides the controlled release of the active agents from the composition with low viscosity.24 cl, 16 dwg, ex 18
Pharmaceutical preparation for rheumatological diseases treatment // 2627424
FIELD: pharmacology.SUBSTANCE: pharmaceutical preparation in the form of a solution for use in rheumatological diseases treatment contains a combination comprising sodium diclofenac or naproxen sodium, betamethasone sodium phosphate and hydroxy-cobalamin sulfate as active substances and benzyl alcohol, propylene glycol, sodium metabisulphite and water for injection as auxiliary components. A method for production of the preparation is described as well.EFFECT: stable, effective formulation with analgesic, anti-inflammatory and antineurotic effects.4 cl, 1 tbl, 4 ex
Starch-free soft chewing gums // 2627420
FIELD: pharmacology.SUBSTANCE: group of inventions refers to a soft chewing gum, which comprises: (a) a pharmaceutically effective amount of at least one active ingredient; (b) a flavoring agent of animal origin; (c) at least 10 wt % of a disintegrating agent in the final composition, which is selected from the group consisting of i) carmellose calcium, ii) directly compressible mannitol, and iii) a mixture or combination of croscarmellose sodium and directly compressible mannitol; (d) at least 10 wt % of a wetting agent in the final composition; (e) a binding agent; (f) an antioxidant; (g) optionally, a preservative; and (h) water; where the soft chewing gum contains less than about 2 wt % of each of polyethylene glycol (PEG), propylene glycol, starch, soy products and wax. Also, the group of inventions refers to a method for the said soft chewing gum production.EFFECT: short time of soft chewing gum decomposition, retained even after prolonged storage at elevated temperature.11 cl, 1 ex, 4 tbl, 3 dwg

Sustainable crystalline modifications of chloride dotap // 2627354
FIELD: chemistry.SUBSTANCE: invention relates to a method of manufacturing crystalline form of chloride (2R, S)-, (2S)- or (2R)-DOTAP (N, N, N-trimethyl-2,3-bis [[(9Z) -1-oxo -9-octadecenyl] oxy]-1-propanamide chloride). The process comprises crystallization chloride (2R, S)-, (2S)- or (2R)-DOTAP of one or more aprotic solvents, wherein the crystallisation takes place by cooling slowly from 35°C to -12°C for constituting 12 hours, or by slowly cooling from a temperature lower than the time period 35°. C over a period of time ranging from 10 to 50 parts crystalline chloride (2R, S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.6, 19.5, 20.2, 21.5 and 25.2; or 2 theta values, comprising at least the values of 6.5, 12.6, 13.4, 19.5, 20.2, 21.5, 25.2 and 29.8; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 1. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 2. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 3. X-ray powder diffractometry was carried out using Cu as a radiation source.EFFECT: proposed method allows to obtain crystalline forms of chloride with improved stability and purity.8 cl, 12 dwg, 5 tbl, 5 ex

Glycosylated polypeptides and medicinal compositions containing these polypeptides // 2627184
FIELD: biotechnology.SUBSTANCE: glycosylated somatostatin analogs containing two or three glycosylated amino acids are obtained.EFFECT: invention allows to increase the stability of somatostatin analogues in blood in comparison with somatostatin.14 cl, 20 dwg, 10 tbl, 91 ex

New modulators and methods of their application // 2627176
FIELD: biotechnology.SUBSTANCE: antibody specifically binding to PTK7 (human protein tyrosine kinase 7), as well as a conjugate of the said antibody with a cytotoxic agent, is claimed. Nucleic acids encoding the antibody are also provided and include expression vectors and host cells. In addition, methods for application of the said antibody, including conjugate, for cancer diagnosis and treatment are provided.EFFECT: effective targeting of tumour stem cells, which can be used to treat patients suffering from a wide range of malignant tumours.52 cl, 42 dwg, 5 tbl, 16 ex
Tablet comprising dehydroepiandrosterone (dhea) // 2627111
FIELD: pharmacology.SUBSTANCE: group of inventions relates to tablet for preventing the loss of testosterone, for maintaining physiological levels of androgens, improving sexual function, mood and health, having a weight of 60-120 mg and consisting of: - 60-100 wt % of granules consisting of: 60-85 wt % of dehydroepiandrosterone (DHEA) granules; 6-35 wt % of microcrystalline cellulose granules; 0-20 wt % of granules of one or more pharmaceutically acceptable granule ingredients; and - 0-40 wt % of one or more pharmaceutically acceptable tablet components, as well as to method of preparing the mentioned tablets.EFFECT: preparation of small tablets with a high content of DHEA, having acceptable release profile.18 cl, 10 ex

Prodrug compositions with high degree of penetration based on peptides and related compounds // 2627065
FIELD: pharmacology.SUBSTANCE: invention relates to compositions with a high degree of penetration or prodrugs with a high degree of penetration based on a peptide or a peptide-related compound that contain a functional unit, a linker and a transport unit. The functional unit is covalently bound to the transport unit via the linker and comprises a peptide or peptide-related compound fragment. The transport unit comprises an amino group capable of being protonated. The linker comprises a bond capable of cleavage after composition penetration through a biological barrier.EFFECT: increased penetration.27 cl, 2 dwg, 16 tbl, 6 ex

ethod of producing nanocapsules of biopaga-d mixture with diamond green // 2626836
FIELD: nanotechnology.SUBSTANCE: method of obtaining nanocapsules of a biopag-D mixture with a diamond green is proposed. The way is that to 2.5 grams Biopag-D is added 2.5 ml of brilliant green, the resulting mixture is added to the suspension 2.5 grams or 7.5 g Apple or citrus pectin in petroleum ether and 0.05 g Preparation E472c as a surfactant, the obtained mixture is put on a magnetic stirrer and stirring is carried out, the precipitated nanocapsule suspension is filtered on a 16 grade porous Schott filter, washed with petroleum ether, dried in a desiccator over calcium chloride. A distinctive feature of the proposed method is the use as an envelope of nanocapsules of apple or citrus pectins.EFFECT: nanocapsules manufacture process simplification and acceleration and weight yield increase.2 dwg, 9 ex

ethod of obtaining nanocaphul l-arginine in the hellan samples // 2626831
FIELD: nanotechnology.SUBSTANCE: L-arginine is used as the nucleus, and gellan gum is used as the envelope of nanocapsules at the mass ratio of the core: shell 1:1, 1:2, or 1:3, respectively. The method is that L-arginine is slowly added to a suspension of gellan gum in butyl alcohol in the presence of 0.01 E472c preparation as a surfactant with stirring at 1,300 rpm. Then 5 ml of diethyl ether are poured, the resulting suspension is filtered off and dried at room temperature.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.1 dwg, 4 ex

ethod of producing nanocapsules of reservoir in kappa-carrageenan // 2626828
FIELD: nanotechnology.SUBSTANCE: kappa-carrageenan is used as the nanocapsule shell, and resveratrol is used as the core for the mass ratio of the shell: the core is 3:1 and 1:5. Resveratrol is slowly added to the kappa-carrageenan slurry in butanol in the presence of 0.01 g E472 c as a surfactant with stirring at 1000 rpm, then butyl chloride is added. The resulting suspension is filtered and dried at the room temperature.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.1 dwg,1 tbl
Drug for body soft tissue disorders treatment // 2626671
FIELD: medicine.SUBSTANCE: proposed drug has the form of a powder and contains a nitrogen-containing drug substance that generates nitrogen monoxide in the affected tissue, namely sodium nitrite or nitrofural or furazoline or furadonin or furagin or its potassium salt or metronidazole or nitroxoline, as well as cytochrome C, ascorbic acid or sodium ascorbate, zinc oxide, and auxiliary substances (starch or sodium salt of carboxymethyl cellulose, or hydroxypropyl cellulose or hydroxypropylcellulose) and talc.EFFECT: implementation of the invention allows to obtain a drug exhibiting high efficacy in treatment of long-lasting body soft tissue damages, including wounds, burns, trophic skin ulcers, pressure ulcers and other various skin lesions.3 cl, 3 tbl, 16 ex
Concentrated protein pharmaceutical compositions and their application // 2626512
FIELD: pharmacology.SUBSTANCE: group of inventions concerns low-viscosity hypotonic pharmaceutical compositions containing a concentrated PRO 140 monoclonal antibody in an amount of 100 to 200 mg/ml, a tonicity regulator in the form of a salt selected from sodium chloride, sodium gluconate or sodium lactate in an amount of 90 to 95 mM, and a buffer solution. They are used in pharmaceutical compositions and finished products.EFFECT: possibility of subcutaneous administration or delivery of a high concentration of a protein drug, such as PRO 140 monoclonal antibody, to a subject suffering from a disease or condition that can be cured with the said protein drug.81 cl, 7 ex, 1 tbl
ethod of betulin nanocapsules production // 2626508
FIELD: nanotechnology.SUBSTANCE: betulin is added to the suspension of agar-agar in petroleum ether in the presence of 0.01 g. of the surfactant E472c, wherein the core to shell weight ratio is 2:1, 1:1 or 1:3 when recalculating to dry matter, then, with stirring at 1300 rpm, ethyl acetate is added, the resulting suspension is filtered and dried at room temperature.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.3 ex
ethod of obtaining chloralhydrate nanocapsules in sodium alginate // 2626507
FIELD: nanotechnology.SUBSTANCE: into a slurry of sodium alginate in hexane and 0.01 g of E472c as a surfactant, chloral hydrate powder is added, then methyl ethyl ketone is added. The ratio of the amount of chloral hydrate and the amount of sodium alginate is 1:1 or 1:3, the resulting suspension is filtered off and dried.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.3 ex

ethod and composition for production of dry lyophilized forms of anthocyanins // 2626505
FIELD: biotechnology.SUBSTANCE: anthocyanin extract obtained from petals of a red curb rose, or chokeberry fruit, or nasturtium petals, purified by the sorption-desorption method using a sorbent is added to a polysaccharide matrix selected from agar-agar or maltodextrin, or arabinogalactan or carrageenan, at the following weight ratio: purified anthocyanins extract:polysaccharide matrix from 1:100 to 1:200, the mixture is stirred until a homogeneous mass is obtained, the resulting sample is frozen at a temperature of minus 18-20°C for at least 48 hours, after which lyophilization is carried out for 8-10 hours at a temperature of minus 50°C and a pressure of 0.1 mBar. The invention also relates to a composition for dry lyophilized forms of anthocyanins production by this method.EFFECT: production of dry forms of anthocyanins, readily soluble in water and having good preservation for at least six months, reduced loss of anthocyanins in the process of obtaining of a lyophilized form.2 cl, 1 dwg, 1 tbl, 9 ex

Nicotine pharmaceutical form // 2625836
FIELD: pharmacology.SUBSTANCE: nicotine-containing mucoadhesive film and method of producing nicotine-containing mucoadhesive film by preparing an aqueous solution with pH value from 9.5 to 13 are described, wherein the mentioned solution comprises (i) a nicotine salt, (ii) an alkaline pH-adjusting agent, and (iii) a film-forming agent containing monovalent cation alginate or a mixture of monovalent cations alginates, wherein the film-forming agent has an average content of guluronate (G) from 50 to 85 wt %, average content of mannuronate (M) from 15 to 50 wt %, average molecular weight from 30,000 to 90,000 g/mol, and its 10% aqueous solution has a viscosity of 100-1000 mPa/s at 20°C, measured at a shear rate of 20 r/min on a Brookfield viscometer with spindle 2; applying of the solution onto a solid surface; and drying of the solution on the mentioned surface.EFFECT: method enables to maintain the nicotine content while storing.24 cl, 1 dwg, 6 tbl, ex 3
Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophene-5-yl)etoxy)propyl)azetidine-3-ol or its salt // 2625767
FIELD: pharmacology.SUBSTANCE: solid pharmaceutical formulation as a pill, comprising 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ol or a salt thereof in an amount of 30% to 90% The said pill also contains a component selected from mannitol, sorbitol and isomaltose in an amount of 6% to 60% by weight, and a disintegrant selected from the group consisting of cellulose derivatives, starch derivatives and polypyrrolidone derivatives in an amount of 3% to 10% by weight.EFFECT: invention provides excellent solubility, hardness for dosage forms and increased stability in long-term storage.11 cl, 15 ex, 5 tbl

ethod for producing sodium hydrogen carbonate nanocapsules in carrageenan // 2625764
FIELD: nanotechnology.SUBSTANCE: sodium bicarbonate is dispersed in carrageena suspension in petroleum ether with the presence of 0.01 g of E472c preparation as a surfactant with stirring at 1200 rpm, then methylene chloride is poured. The mass ratio of core: shell is 1:1, 1:2, 1:3 or 1:5 in terms of dry substance, the resulting suspension is filtered off and dried at room temperature.EFFECT: simplifying and accelerating the nanocapsule obtaining process, reducing the losses when obtaining nanocapsules.2 dwg, 5 ex
Stimulus-sensitive material and medical material containing it // 2625761
FIELD: medicine.SUBSTANCE: temperature-sensitive medical anti-solder material contains a temperature-sensitive polymer in an amount of 10-50 wt %, fibers in an amount of 0.5-10 wt % and water, where the fibers dispersed in the temperature sensitive polymer have a number-average diameter of 1 to 900 nm. The temperature-sensitive polymer and fiber have a common basic chemical structure selected from the following combinations: the fiber includes lactic acid units -O-CH(CH3)-CO-, while the temperature-sensitive polymer includes lactic acid units -O-CH(CH3)-CO-, or the fiber includes nylon 6 -CH2CH2CH2CH2CH2-CO-NH-. The temperature-sensitive polymer includes amide units -CO-NH-, and the weight ratio of the temperature-sensitive polymer to the fibers is 5 to 100. The invention provides creation of a material in which both ease of use and mechanical properties are achieved at the same time.EFFECT: invention is favorable for sol-gel transition of between the liquid and solid state.10 cl, 2 tbl, 13 ex

Pharmaceutical composition for histone deacetylase inhibitors // 2625758
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for topical application is shown. It comprises of a therapeutically effective amount of active pharmaceutical ingredient (API) - a compound of the structural formula of at least one acidifying agent and a base carrier comprising of at least one pharmaceutically acceptable nonaqueous solvent. The acidifying agent is separated from citric acid, acetic acid and phosphoric acid. The measured pH value of the pharmaceutical composition is from 3 to 5. Preferably, the pharmaceutically acceptable nonaqueous solvent is a mixture of ethanol and propylene glycol. Also, a kit for preparing a pharmaceutical composition and a method for treating a proliferative, immune and skin diseases in a subject are desribed. The values of n, R1 and R2 in the structural formula (I) are defined in the claims.EFFECT: stabilized pharmaceutical composition is obtained.26 cl, 1 dwg, 18 tbl, 3 ex
Water-based liquid composition with bromfenac possessing preservative effectiveness // 2625755
FIELD: chemistry.SUBSTANCE: invention represents the use of bromfenac or its salt to improve the preservative effectiveness of the water-based liquid composition, comprising (a) bromfenac or its salt and (b) benzalkonium chloride, and c) at least one agent selected from the group consisting of nonionic surfactant and water-soluble polymer. The invention also relates to a method of improving the preservative effectiveness of the aqueous solution described above, which comprises adding of bromfenac or its salt in an amount of 0.1 w/v % to the solution.EFFECT: invention enables to obtain a composition with imroved preservative activity, wherein there are low concentrations of benzalkonium chloride preserving agent.10 cl, 21 tbl, 4 ex
Granulates containing eslicarbazepine acetate // 2625747
FIELD: pharmacology.SUBSTANCE: solid pharmaceutical granular composition is described. It contains eslicarbazepine acetate and excipients. In this case, at least 90% of the granules of the composition have a particle size of 1200 microns or less and at least 90% of the granules of the composition have a particle size of 90 microns or more and/or at least 50% of the granules of the composition have a particle size of 250 microns or more. These granules have a specific particle size, determined by the method of screening. Also, a method for producing a pharmaceutical granular composition of eslicarbazepine acetate is disclosed.EFFECT: inventions provide a uniform distribution of the granules with a low number of small and large particles.68 cl, 5 ex, 5 tbl, 7 dwg
Pharmacological composition on basis of iron compounds // 2625739
FIELD: pharmacology.SUBSTANCE: invention is a pharmacological composition containing the iron (II) sulphate for treatment of iron deficiency anemia, characterised in that it additionally contains iron hexacyanoferrate, iron-potassium hexacyanoferrate, potassium sulfate and micro cellulose, the components in the composition being in a certain ratio, in weight percent.EFFECT: high therapeutic efficacy, good tolerability, and low toxicity.2 cl, 5 ex
Effervescent phytomineral complex with antidiabetic action // 2625737
FIELD: pharmacology.SUBSTANCE: effervescent phytomineral complex with antidiabetic action, containing an extract of forest dry gurmar, calcium carbonate, sodium chloride, potassium iodide, potassium bromide, anhydrous sodium sulfate, anhydrous magnesium sulfate, anhydrous citric acid, sodium hydrogen carbonate, trilon-B, medium molecular polyvinylpyrrolidone, polyethylene glycol with a molar mass of 6000, MAE 100P kolliecoat. The complex contains acidic and carbonate fractions obtained by separate granulation, where the acid fraction includes an extract of forest dry gurmar, citric acid, sodium chloride, potassium chloride, anhydrous sodium sulfate, anhydrous magnesium sulfate, and the carbonate fraction includes sodium bicarbonate, calcium carbonate, potassium iodide and potassium bromide. At the stage of carbonate fraction formation, prior to granulation, trilon-B, medium molecular polyvinylpyrrolidone are added to the carbonate fraction, after carbonate fraction granulation, polyethylene glycol 6000 is added to it, and MAE 100P kolliecoat is added to the composition of the acid fraction for granulation. The complex contains components at a certain ratio.EFFECT: complex has improved adsorption, has a predictable and stable pharmacokinetic profile, transport time in the small intestine is reduced to 20 minutes.1 tbl

Anis-aromatised drug // 2625550
FIELD: pharmacology.SUBSTANCE: liquid drug contains phenylephrine and an anethole analog which is substantially free of aldehyde groups, the anethole analog being selected from the group consisting of 1-methoxy-4-n-propylbenzene, methylanisate, 2-chloranethol, 2,6-dichloroanethanol, 3-nitroanethanol, 3,5-dinitroanethole, 3-cyanoanethanol, 3,5-dicyanoanethanol, 1-methoxy-3-(1-propenyl)benzene and combinations thereof. A method for determination of the phenylephrine decomposition rate involves application of an automated flow reaction and incubation control apparatus for the forced disintegration of a liquid drug using a temperature change in the range of 80°C to 140°C at a pressure of 6-7 bar for 20 minutes with fixed increments. The amount of phenylephrine in the sample is then determined and the rate of drug disintegration is determined.EFFECT: invention allows to obtain an anis-aromatised liquid drug containing phenyphrine with a shelf life of 18 months.12 cl, 2 tbl, 3 dwg, 14 ex

ethod of production of antiseptic dorogov's stimulator (ads) nanocapsules fraction 2 in carrageenan // 2625547
FIELD: nanotechnology.SUBSTANCE: invention relates to a method of production of antiseptic Dorogov's stimulator (ADS) nanocapsules 2 fraction in carrageenan. This method is characterized in that the ASD 2 fraction is dispersed in a solution of carrageenan in benzene in the presence of E472c preparation as a surfactant in stirring at 1,300 rpm, then 10 ml of sulphuric ether are added, the resulting suspension is filtered off and dried at room temperature. The mass ratio core: shell is 1:1, 1:3 or 3:1.EFFECT: simplification and acceleration of the process of producing the nanocapsules, as well as increase in their yield by weight.3 dwg, 4 ex
Pharmaceutical aerosol composition and method for pharmaceutical composition production // 2625504
FIELD: pharmacology.SUBSTANCE: pharmaceutical drug composition for treatment of wounds and other skin defects consists of 0.1-99.9% vinyl butyl polyether, 0.1-99.9% of low boiling aliphatic ester as a solvent, and a pharmaceutically acceptable carrier gas. Diethyl ether is used, in particular, as a low-boiling aliphatic ester.EFFECT: method for pharmaceutical composition preparation is based on vinyl butyl polyester dilution in low boiling aliphatic ether, sterile filtration and applicator filling under pressure, together with a carrier gas dose under conditions ensuring mixture sterility.10 cl, 4 ex, 2 tbl

ethod for obtaining nanocapules of rosehip dry extract // 2625501
FIELD: food industry.SUBSTANCE: method is characterized by the fact that 1 g of dry rosehip extract is dispersed in the suspension of sodium alginate in benzene, containing 1 g or 3 g of said polymer, in the presence of 0.01 g of the preparation E472c as a surfactant with stirring at 1300 rpm, then 5 ml of acetonitrile are added, the precipitate formed is filtered off and dried at room temperature.EFFECT: simplifying and accelerating the process of obtaining rosehip extract nanocapsules, increasing their yield by weight.1 dwg, 4 ex

Ophthalmic composition // 2625301
FIELD: pharmacology.SUBSTANCE: ophthalmic composition contains a formula compound, where the values for R1 and R2 groups are given in the claims, and an ophthalmologically acceptable carrier. The invention also relates to a method for dry eye treatment, comprising local administration of a therapeutically effective amount of the ophthalmic composition to the eye of the subject in need.EFFECT: increased efficiency.20 cl, 6 dwg, 6 ex
 
2551113.
Up!